RU2003119460A - Применение пэг-интерферона-а(пэг-inf-а) и рибавирина для лечения хронического гепатита с - Google Patents
Применение пэг-интерферона-а(пэг-inf-а) и рибавирина для лечения хронического гепатита сInfo
- Publication number
- RU2003119460A RU2003119460A RU2003119460/14A RU2003119460A RU2003119460A RU 2003119460 A RU2003119460 A RU 2003119460A RU 2003119460/14 A RU2003119460/14 A RU 2003119460/14A RU 2003119460 A RU2003119460 A RU 2003119460A RU 2003119460 A RU2003119460 A RU 2003119460A
- Authority
- RU
- Russia
- Prior art keywords
- peg
- ifn
- ribavirin
- conjugate
- chronic hepatitis
- Prior art date
Links
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 title claims 6
- 229960000329 ribavirin Drugs 0.000 title claims 6
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 title claims 6
- 208000006154 Chronic hepatitis C Diseases 0.000 title claims 5
- 208000005176 Hepatitis C Diseases 0.000 title claims 5
- 208000010710 hepatitis C virus infection Diseases 0.000 title claims 5
- 238000000034 method Methods 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 2
- 108010092853 peginterferon alfa-2a Proteins 0.000 claims 2
- 229940126601 medicinal product Drugs 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
Claims (9)
1. Применение конъюгатов ПЭГ-IFN-α в сочетании с рибавирином для приготовления лекарственного средства, предназначенного для лечения заболеваний хроническим гепатитом С.
2. Применение по п.1, где количество конъюгата ПЭГ-IFN-α составляет приблизительно от 33 до 540 мкг/неделю.
3. Применение по п.1, где количество рибавирина составляет от 400 до 1200 мг/день.
4. Применение по п.п.1-3, где конъюгат ПЭГ-IFN-α представляет собой конъюгат ПЭГ-IFN-α2А формулы
где R и R’ обозначают метил, Х обозначает NH и n и n’ каждый по отдельности или оба равны 420 или 520.
5. Способ лечения заболевания хроническим гепатитом С, предусматривающий введение конъюгата ПЭГ-IFN-α в сочетании с рибавирином в количествах, эффективных для лечения хронического гепатита С.
6. Способ по п.5, где количество конъюгата ПЭГ-IFN-α, вводимого согласно указанному способу, составляет приблизительно 33-540 мкг/неделю.
7. Способ по п.5, где количество рибавирина, вводимого согласно указанному способу, составляет 400-1200 мг/день.
8. Способ по любому из п.п.5-7, где вводимый конъюгат ПЭГ-IFN-α представляет собой ПЭГ-IFN-α2А.
9. Применение конъюгата ПЭГ-IFN-α и рибавирина для лечения заболеваний хроническим гепатитом С.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98110433 | 1998-06-08 | ||
| EP98110433.4 | 1998-06-08 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2001101445/14A Division RU2001101445A (ru) | 1998-06-08 | 1999-05-29 | Применение пэг-интерферона-альфа (пэг-ifn-альфа) и рибавирина для лечения хронического гепатита с |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2003119460A true RU2003119460A (ru) | 2004-12-20 |
| RU2271217C2 RU2271217C2 (ru) | 2006-03-10 |
Family
ID=8232086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003119460/14A RU2271217C2 (ru) | 1998-06-08 | 1999-05-29 | ПРИМЕНЕНИЕ ПЭГ-ИНТЕРФЕРОНА-α(ПЭГ-IFN-α) И РИБАВИРИНА ДЛЯ ЛЕЧЕНИЯ ХРОНИЧЕСКОГО ГЕПАТИТА С |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US20030053986A1 (ru) |
| EP (1) | EP1087778B1 (ru) |
| JP (2) | JP3839667B2 (ru) |
| KR (2) | KR20050055053A (ru) |
| CN (1) | CN1170543C (ru) |
| AR (1) | AR019855A1 (ru) |
| AT (1) | ATE307597T1 (ru) |
| AU (1) | AU767131B2 (ru) |
| BR (1) | BR9911076A (ru) |
| CA (1) | CA2334267C (ru) |
| CL (1) | CL2010000828A1 (ru) |
| CO (1) | CO5050297A1 (ru) |
| CZ (1) | CZ298681B6 (ru) |
| DE (1) | DE69927971T2 (ru) |
| DK (1) | DK1087778T3 (ru) |
| ES (1) | ES2251196T3 (ru) |
| HR (1) | HRP20000808A2 (ru) |
| HU (1) | HU228218B1 (ru) |
| ID (1) | ID29285A (ru) |
| IL (2) | IL139786A0 (ru) |
| MA (1) | MA26641A1 (ru) |
| MY (1) | MY124091A (ru) |
| NO (1) | NO325598B1 (ru) |
| NZ (1) | NZ508249A (ru) |
| PE (1) | PE20000560A1 (ru) |
| PL (1) | PL192364B1 (ru) |
| RS (1) | RS50144B (ru) |
| RU (1) | RU2271217C2 (ru) |
| SA (1) | SA99200208B1 (ru) |
| SI (1) | SI1087778T1 (ru) |
| TR (1) | TR200003635T2 (ru) |
| TW (1) | TWI241913B (ru) |
| WO (1) | WO1999064016A1 (ru) |
| ZA (1) | ZA200006814B (ru) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS50144B (sr) * | 1998-06-08 | 2009-03-25 | F. Hoffmann-La Roche Ag., | Primena peg-inf-alfa 2a i ribavirina za proizvodnju leka za lečenje hroničnog hepatitisa c |
| MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| NZ547204A (en) | 2000-05-26 | 2008-01-31 | Idenix Cayman Ltd | Methods and compositions for treating flaviviruses and pestiviruses |
| KR100851861B1 (ko) * | 2000-08-07 | 2008-08-13 | 사이클론 파아머슈티컬 인코오퍼레이티드 | 티모신, 인터페론 및 리바비린을 사용한 씨 형 간염의치료 |
| US7208167B2 (en) | 2000-08-07 | 2007-04-24 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis C with thymosin and peptide combination therapy |
| US7179791B2 (en) | 2001-01-11 | 2007-02-20 | Duke University | Inhibiting GS-FDH to modulate NO bioactivity |
| US7138376B2 (en) | 2001-09-28 | 2006-11-21 | Idenix Pharmaceuticals, Inc. | Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides |
| KR100480429B1 (ko) * | 2001-12-04 | 2005-04-06 | 선바이오(주) | 인터페론-알파와 폴리에틸렌글리콜 유도체의 배합체 |
| NZ537662A (en) | 2002-06-28 | 2007-10-26 | Idenix Cayman Ltd | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| MY140819A (en) | 2002-06-28 | 2010-01-29 | Idenix Caymans Ltd | Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae |
| AU2003248748A1 (en) | 2002-06-28 | 2004-01-19 | Idenix (Cayman) Limited | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| US7824851B2 (en) * | 2002-11-15 | 2010-11-02 | Idenix Pharmaceuticals, Inc. | 2′-branched nucleosides and Flaviviridae mutation |
| KR20050109918A (ko) | 2002-12-12 | 2005-11-22 | 이데닉스 (케이만) 리미티드 | 2'-분지형 뉴클레오시드의 제조 방법 |
| NZ540913A (en) * | 2002-12-23 | 2008-02-29 | Idenix Cayman Ltd | Process for the production of 3'-nucleoside prodrugs |
| CA2734052A1 (en) | 2003-05-30 | 2005-01-13 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
| BRPI0512360A (pt) * | 2004-06-23 | 2008-03-11 | Idenix Cayman Ltd | derivados de 5-aza-7-deazapurina para o tratamento de flaviviridae |
| US8886272B2 (en) | 2004-07-13 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
| CN101023094B (zh) | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备 |
| BRPI0515279A (pt) | 2004-09-14 | 2008-07-15 | Pharmasset Inc | preparação de ribofuranosil pirimidinas e purinas 2'fluoro-2'-alquil- substituìdas ou outras opcionalmente substituìdas e seus derivados |
| EP2899277A1 (en) | 2004-11-26 | 2015-07-29 | Pieris AG | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| BRPI0614863A2 (pt) * | 2005-08-15 | 2011-04-19 | Hoffmann La Roche | uso de conjugados de peg-ifn-alfa em associação a ribavirina, bem como kit compreendendo os mesmos |
| US9201979B2 (en) * | 2005-09-14 | 2015-12-01 | Millennial Media, Inc. | Syndication of a behavioral profile associated with an availability condition using a monetization platform |
| WO2007075876A2 (en) * | 2005-12-23 | 2007-07-05 | Idenix Pharmaceuticals, Inc. | Process for preparing a synthetic intermediate for preparation of branched nucleosides |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| TW200946541A (en) | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
| JP5711118B2 (ja) | 2008-06-24 | 2015-04-30 | テクニッシュ ウニヴェルジテート ミュンヘン | 所与の標的に対してアフィニティーを有するｈＮＧＡＬおよび類縁タンパク質のムテイン |
| AU2009293493B2 (en) * | 2008-09-17 | 2014-09-18 | Boehringer Ingelheim International Gmbh | Combination of HCV NS3 protease inhibitor with interferon and ribavirin |
| US8716262B2 (en) | 2008-12-23 | 2014-05-06 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| WO2010075554A1 (en) | 2008-12-23 | 2010-07-01 | Pharmasset, Inc. | Synthesis of purine nucleosides |
| EP2376514A2 (en) | 2008-12-23 | 2011-10-19 | Pharmasset, Inc. | Nucleoside analogs |
| CN102458470B (zh) | 2009-05-08 | 2016-01-20 | 赛生制药有限公司 | 作为疫苗增强剂的α胸腺素肽 |
| TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| CN102612362A (zh) | 2009-08-05 | 2012-07-25 | 皮里斯股份公司 | 脂质运载蛋白突变蛋白的控制释放制剂 |
| CA2779244A1 (en) | 2009-10-30 | 2011-05-05 | Boehringer Ingelheim International Gmbh | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin |
| EP2510357B1 (en) | 2009-12-07 | 2016-03-30 | Pieris AG | Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target |
| RS54368B1 (sr) | 2010-03-31 | 2016-04-28 | Gilead Pharmasset Llc | Kristalni (s)-izopropil 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-diokso-3,4-dihidropirimidin-1-(2h)-il)-4-fluoro-3-hidroksi-4-metiltetrahidrofuran-2-il)metoksi)(fenoksi)fosforil)amino)propanoat |
| RS58839B1 (sr) | 2010-06-08 | 2019-07-31 | Pieris Pharmaceuticals Gmbh | Muteini lipokalina u suzama koji vezuju il-4 r alfa |
| US9051382B2 (en) | 2010-08-16 | 2015-06-09 | Pieris Ag | Human neutrophil gelatinase-associated lipocalin (hNGAL) muteins that bind hepcidin and nucleic acid encoding such |
| CA2817779C (en) | 2010-11-15 | 2019-02-19 | Pieris Ag | Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) |
| CA2818853A1 (en) | 2010-11-30 | 2012-06-07 | Gilead Pharmasset Llc | 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus |
| EP2646552B1 (en) | 2010-12-02 | 2017-07-05 | Pieris Pharmaceuticals GmbH | Muteins of human lipocalin 2 with affinity for ctla-4 |
| UA116087C2 (uk) | 2011-09-16 | 2018-02-12 | Гіліад Фармассет Елелсі | Композиція для лікування вірусу гепатиту c |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| CN103998053B9 (zh) | 2011-12-13 | 2020-07-21 | 皮里斯制药有限公司 | 通过抑制il-4和/或il-13与其各自的受体结合来预防或治疗某些障碍的方法 |
| US9522940B2 (en) | 2012-05-23 | 2016-12-20 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3 |
| US20140039923A1 (en) * | 2012-08-03 | 2014-02-06 | AxelaCare Health Solutions, Inc. | Computer program, method, and system for receiving and managing patient data gathered during patient treatments |
| WO2014076321A1 (en) | 2012-11-19 | 2014-05-22 | Pieris Ag | Novel specific-binding polypeptides and uses thereof |
| MY172166A (en) | 2013-01-31 | 2019-11-15 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| CN105246503A (zh) | 2013-03-14 | 2016-01-13 | 第一三共株式会社 | Pcsk9的新颖结合蛋白 |
| SG11201600919UA (en) | 2013-08-27 | 2016-03-30 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| WO2015104406A2 (en) | 2014-01-13 | 2015-07-16 | Pieris Ag | Multi-specific polypeptide useful for localized tumor immunomodulation |
| CN106573964B (zh) | 2014-05-22 | 2021-07-16 | 皮里斯制药有限公司 | 新型特异性结合多肽及其用途 |
| KR20170105609A (ko) | 2015-01-28 | 2017-09-19 | 피어이스 파마슈티컬즈 게엠베하 | 신생혈관형성에 특이적인 신규한 단백질 |
| EA035824B1 (ru) | 2015-02-18 | 2020-08-17 | Пайерис Фармасьютикалс Гмбх | Новые белки, специфичные к пиовердину и пиохелину |
| JP6783797B2 (ja) | 2015-05-04 | 2020-11-11 | ピエリス ファーマシューティカルズ ゲーエムベーハー | 抗がん融合ポリペプチド |
| EP3292137B1 (en) | 2015-05-04 | 2022-09-07 | Pieris Pharmaceuticals GmbH | Proteins specific for cd137 |
| SMT202300026T1 (it) | 2015-05-18 | 2023-03-17 | Pieris Pharmaceuticals Gmbh | Polipeptide di fusione anti-cancro |
| CA2982034A1 (en) | 2015-05-18 | 2016-11-24 | Pieris Pharmaceuticals Gmbh | Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) |
| EP3115371A1 (en) | 2015-07-07 | 2017-01-11 | Sanofi | Fusion molecules |
| EP3322433B1 (en) | 2015-07-15 | 2023-05-31 | Pieris Pharmaceuticals GmbH | Novel proteins specific for lag-3 |
| CN108699162A (zh) | 2015-11-30 | 2018-10-23 | 皮里斯澳大利亚有限公司 | 新型抗血管生成融合多肽 |
| TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
| WO2018087108A1 (en) | 2016-11-09 | 2018-05-17 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
| CN110402252A (zh) | 2017-01-18 | 2019-11-01 | 皮里斯制药有限公司 | 对lag-3具有结合亲和力的脂质运载蛋白突变蛋白 |
| MX2021000401A (es) | 2018-07-31 | 2021-03-25 | Pieris Pharmaceuticals Gmbh | Nuevas proteinas de fusion especificas para cd137 y pd-l1. |
| MX2021010039A (es) | 2019-02-26 | 2021-09-21 | Pieris Pharmaceuticals Gmbh | Novedosas proteinas de fusion especificas para cd137 y gpc3. |
| KR20230020443A (ko) | 2020-06-05 | 2023-02-10 | 피어이스 파마슈티컬즈 게엠베하 | 4-1bb 표적화 다량체 면역조절제 |
| KR20230165917A (ko) | 2021-04-08 | 2023-12-05 | 피어이스 파마슈티컬즈 게엠베하 | 결합 조직 성장 인자(ctgf)에 특이적인 신규 리포칼린 뮤테인 |
| WO2022243341A1 (en) | 2021-05-18 | 2022-11-24 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding affinity for ox40 |
| IL319272A (en) | 2022-09-21 | 2025-04-01 | Seagen Inc | ROVEL FUSION protein specific for CD137 and CD228 |
| WO2025175123A1 (en) | 2024-02-16 | 2025-08-21 | Seagen Inc. | Methods of treating cancer using fusion proteins specific for cd137 and cd228 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4211771A (en) * | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
| DE3380726D1 (en) * | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
| US4681848A (en) * | 1982-09-22 | 1987-07-21 | Takeda Chemical Industries, Ltd. | Novel peptide and use thereof |
| GB8430252D0 (en) * | 1984-11-30 | 1985-01-09 | Beecham Group Plc | Compounds |
| US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| DE3719046A1 (de) * | 1987-06-06 | 1988-12-15 | Basf Ag | Verwendung von salzen von sulfonamidcarbonsaeuren als korrosionsinhibitoren in waessrigen systemen |
| US5122614A (en) * | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5238915A (en) * | 1991-02-08 | 1993-08-24 | Wakunaga Seiyaku K.K. | Aromatic composition and method for controlling aroma |
| US5595732A (en) * | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| US5281698A (en) * | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
| US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| US5359030A (en) * | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5643575A (en) * | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5919455A (en) * | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| NZ276943A (en) * | 1993-11-10 | 1998-02-26 | Schering Corp Substituted For | Alpha-interferon conjugated to a non-antigenic polymer (preferably a polyalkylene oxide) and its preparation |
| US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| TW426523B (en) * | 1995-04-06 | 2001-03-21 | Hoffmann La Roche | Interferon solution |
| US5695760A (en) * | 1995-04-24 | 1997-12-09 | Boehringer Inglehiem Pharmaceuticals, Inc. | Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation |
| US6387365B1 (en) * | 1995-05-19 | 2002-05-14 | Schering Corporation | Combination therapy for chronic hepatitis C infection |
| DE69632062T2 (de) * | 1995-11-02 | 2004-11-18 | Schering Corp. | Kontinuierliche, niedrigdosierte zytokine-infusionstherapie |
| US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| TW517067B (en) * | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
| US6172046B1 (en) * | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
| RS50144B (sr) * | 1998-06-08 | 2009-03-25 | F. Hoffmann-La Roche Ag., | Primena peg-inf-alfa 2a i ribavirina za proizvodnju leka za lečenje hroničnog hepatitisa c |
-
1999
- 1999-05-29 RS YUP-770/00A patent/RS50144B/sr unknown
- 1999-05-29 DE DE69927971T patent/DE69927971T2/de not_active Expired - Lifetime
- 1999-05-29 CA CA002334267A patent/CA2334267C/en not_active Expired - Lifetime
- 1999-05-29 IL IL13978699A patent/IL139786A0/xx active IP Right Grant
- 1999-05-29 HU HU0102033A patent/HU228218B1/hu unknown
- 1999-05-29 KR KR1020057009098A patent/KR20050055053A/ko not_active Ceased
- 1999-05-29 NZ NZ508249A patent/NZ508249A/xx not_active IP Right Cessation
- 1999-05-29 HR HR20000808A patent/HRP20000808A2/hr not_active Application Discontinuation
- 1999-05-29 BR BR9911076-8A patent/BR9911076A/pt not_active Application Discontinuation
- 1999-05-29 SI SI9930843T patent/SI1087778T1/sl unknown
- 1999-05-29 JP JP2000553084A patent/JP3839667B2/ja not_active Expired - Lifetime
- 1999-05-29 CN CNB998071706A patent/CN1170543C/zh not_active Expired - Lifetime
- 1999-05-29 WO PCT/EP1999/003746 patent/WO1999064016A1/en not_active Ceased
- 1999-05-29 RU RU2003119460/14A patent/RU2271217C2/ru active
- 1999-05-29 ID IDW20002551A patent/ID29285A/id unknown
- 1999-05-29 PL PL344794A patent/PL192364B1/pl unknown
- 1999-05-29 EP EP99927804A patent/EP1087778B1/en not_active Expired - Lifetime
- 1999-05-29 CZ CZ20004487A patent/CZ298681B6/cs not_active IP Right Cessation
- 1999-05-29 AT AT99927804T patent/ATE307597T1/de active
- 1999-05-29 ES ES99927804T patent/ES2251196T3/es not_active Expired - Lifetime
- 1999-05-29 AU AU45033/99A patent/AU767131B2/en not_active Expired
- 1999-05-29 TR TR2000/03635T patent/TR200003635T2/xx unknown
- 1999-05-29 DK DK99927804T patent/DK1087778T3/da active
- 1999-05-29 KR KR1020007013843A patent/KR20010052622A/ko not_active Ceased
- 1999-06-02 SA SA99200208A patent/SA99200208B1/ar unknown
- 1999-06-04 TW TW088109246A patent/TWI241913B/zh not_active IP Right Cessation
- 1999-06-04 PE PE1999000478A patent/PE20000560A1/es not_active Application Discontinuation
- 1999-06-04 CO CO99035303A patent/CO5050297A1/es unknown
- 1999-06-04 AR ARP990102664A patent/AR019855A1/es not_active Application Discontinuation
- 1999-06-07 MY MYPI99002297A patent/MY124091A/en unknown
- 1999-06-08 MA MA25613A patent/MA26641A1/fr unknown
-
2000
- 2000-11-20 IL IL139786A patent/IL139786A/en not_active IP Right Cessation
- 2000-11-21 ZA ZA200006814A patent/ZA200006814B/en unknown
- 2000-12-05 NO NO20006178A patent/NO325598B1/no not_active IP Right Cessation
-
2001
- 2001-11-07 US US10/037,064 patent/US20030053986A1/en not_active Abandoned
-
2004
- 2004-07-26 US US10/899,726 patent/US20050031589A1/en not_active Abandoned
-
2006
- 2006-02-02 JP JP2006025756A patent/JP2006160759A/ja active Pending
-
2007
- 2007-01-24 US US11/657,287 patent/US20070196385A1/en not_active Abandoned
-
2010
- 2010-08-04 CL CL2010000828A patent/CL2010000828A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2003119460A (ru) | Применение пэг-интерферона-а(пэг-inf-а) и рибавирина для лечения хронического гепатита с | |
| BR9911076A (pt) | Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica | |
| CY1105707T1 (el) | Συνδυασμοι φορμοτερολης και ενος αλατος τριοτροπιου | |
| RU2004110055A (ru) | Новые ингибиторы дипептидил пептидазы iv в качестве антидиабетических агентов | |
| DE60316779D1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| CA2182228A1 (en) | Codrugs as a method of controlled drug delivery | |
| CY1111088T1 (el) | Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση | |
| ATE170077T1 (de) | Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'- halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff | |
| EP1431286A3 (en) | Prodigiosin derivatives for treating cancer or viral diseases | |
| DE69824313D1 (de) | Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen | |
| JP2003514025A5 (ru) | ||
| KR960003729A (ko) | 항과혈당증 작용을 지닌 약제 | |
| TR200200401T2 (tr) | PEG-IFN-a ile birlikte mikofenolat mofetil | |
| AR022116A1 (es) | Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa | |
| RU2004121687A (ru) | Композиции, содержащие эпотилоны, и их применение для лечения карциноидного синдрома | |
| RU96103685A (ru) | 1,2,5-тиадиазольные производные индолилалкил-пиридинил- и пиримидинил-пиперазинов, способ лечения или предотвращения развития сосудистой головной боли и фармацевтическая композиция | |
| KR890012942A (ko) | 5-치환된 오르니틴 유도체 | |
| RU2001101445A (ru) | Применение пэг-интерферона-альфа (пэг-ifn-альфа) и рибавирина для лечения хронического гепатита с | |
| EA200400348A1 (ru) | Цисплатиновые составы пониженной токсичности и способы их применения | |
| AR025549A1 (es) | Mofetil micofelonato en asociacion con peg-ifn-alfa | |
| RU2008109649A (ru) | ПЭГ-IFNα И РИБАВИРИН ДЛЯ ЛЕЧЕНИЯ ВИРУСА ГЕПАТИТА В | |
| CA2343120A1 (en) | Use of an anthracycline derivative for the treatment of a liver tumor | |
| KR930702985A (ko) | 식도암의 치료 | |
| RU2004116067A (ru) | Фармацевтические композиции, содержащие макролиды | |
| RU99118510A (ru) | Композиция для лечения или предупреждения рака простаты |